骨髓移植市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、治療類型、地區和競爭格局分類，2021-2031年

全球骨髓移植市場預計將從 2025 年的 129.9 億美元成長到 2031 年的 172.8 億美元，複合年成長率為 4.87%。

造血幹細胞移植，也稱為造血幹細胞移植，是一種複雜的治療手術，透過用健康的幹細胞取代受損的骨髓來治療淋巴瘤、白血病和骨髓瘤等惡性腫瘤。市場成長的主要驅動力是血液癌症發生率的上升以及單倍體相合移植技術的進步，後者使得非同胞供者也能獲得完全匹配的捐贈者。全球擴大供體庫的努力也促進了這一成長。世界骨髓捐贈者協會（WMDA）報告稱，到2024年，其國際登記處已登記了超過4400萬名志願者捐贈者和臍帶血製品，這大大提高了不同患者匹配成功的可能性。

然而，該市場面臨一個重大障礙：手術及長期管理費用高昂。這些經濟負擔包括移植前預處理、手術本身以及移植物抗宿主疾病等併發症的長期照護。這種經濟負擔限制了移植服務的可近性，尤其是在醫療基礎設施不發達或報銷體係不完善的地區。

市場促進因素

骨髓惡性腫瘤發生率的上升是推動市場成長的主要動力，造血幹細胞移植（HSCT）作為根治性白血病、骨髓瘤和淋巴瘤等疾病的必要治療方法，其重要性日益凸顯。不斷加重的癌症負擔推動了全球對移植手術的持續需求。美國癌症協會於2025年1月發布的《2025年癌症事實與數據》報告也印證了這一趨勢，該報告預測，僅當年美國就將新增66,890例白血病病例和89,070例淋巴瘤病例，凸顯了這些治療方法在控制危及生命的血液系統疾病方面的重要性。

此外，造血幹細胞移植（HSCT）技術的進步，特別是單倍體相合通訊協定的進步，透過緩解捐贈者短缺問題，正在擴大市場。移植物抗宿主疾病（GVHD）預防方面的創新，例如移植後使用Cyclophosphamide，已使部分相合的親緣供體成為標準選擇，從而減少了對完全相合的非親緣供體的需求。國際血液和骨髓移植中心（CIBMT）在2025年8月報告稱，2023年單倍體相合供體佔所有異基因移植的21%。這一適應症的擴大也反映在移植數量的成長上。根據歐洲血液和骨髓移植協會2025年2月的報告，2023年共進行了47,731例移植手術，比前一年增加了7.8%。

市場挑戰

骨髓移植及其後續治療的高昂費用是市場成長的主要障礙。這一經濟障礙源於手術的複雜性、嚴格的移植前準備以及必要的長期術後監測。因此，許多醫療保險不足或居住在醫療預算有限的地區的患者無法獲得這些救命治療，從而縮小了潛在市場規模。此外，建造專業設施需要大量資金投入，這意味著服務主要集中在富裕地區，醫療基礎設施落後地區的人們無法獲得足夠的醫療服務。

移植手術帶來的經濟負擔因治療移植物抗宿主疾病等併發症的費用而進一步加重，這些併發症涉及昂貴的藥物以及再次入院的可能性。根據美國血液學會統計，2024年移植手術期間每位病患的醫療費用中位數約為331,827美元。這些高昂的費用往往導致保險公司拒付率居高不下，患者需要承擔巨額自付費用，造成經濟摩擦，這限制了每年的手術數量，儘管臨床需求不斷成長。

市場趨勢

基因編輯造血幹細胞療法的興起代表著該行業的模式轉移，它為無需依賴匹配供體的遺傳性血液疾病提供了根治性療法。這一趨勢涉及將自體幹細胞在體外進行基因修飾，從而消除移植物抗宿主疾病的風險，並擴大其適用患者群體。近期財務數據表明，這種方法具有市場可行性。 2025年11月，Vertex Pharmaceuticals在第三季財報中報告稱，其基因編輯療法Casgevy已創造1,700萬美元的收入，凸顯了這些先進基因介入療法的快速普及和立竿見影的效果。

同時，將人工智慧（AI）整合到供體配型中，透過改進人類白血球抗原（HLA）的選擇和風險評估，正在革新移植前的流程。先進的機器學習演算法現在被用於解讀複雜的生物學數據，使臨床醫生比傳統方法更準確地預測移植結果和併發症。這種向數據驅動型改進的轉變正在推動醫療保健水準的提升。 2025年3月，RPH報告稱，其客製化的AI模型在預測幹細胞移植存活率方面達到了89%的準確率，這表明該領域正朝著個人化醫療的方向邁出重要一步。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球骨髓移植市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（自體移植、異體移植、其他）
  • 依類型治療（白血病、淋巴瘤、骨髓瘤、骨髓發育不良症候群、骨髓增殖性疾病、再生障礙性貧血、固態腫瘤、鐮狀細胞貧血、地中海貧血、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美骨髓移植市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲骨髓移植市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區骨髓移植市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲骨髓移植市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲骨髓移植市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球骨髓移植市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Merck KGaA
• SANOFI WINTHROP INDUSTRIE
• AllCells, LLC
• STEMCELL Technologies Canada Inc.
• American Type Culture Collection
• Charles River Laboratories International, Inc.
• Fujifilm Cellular Dynamics, Inc.
• ReachBio LLC
• PromoCell GmbH
• Mesoblast Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Bone Marrow Transplant Market is projected to expand from USD 12.99 Billion in 2025 to USD 17.28 Billion by 2031, reflecting a compound annual growth rate of 4.87%. Also termed hematopoietic stem cell transplantation, this complex procedure replaces damaged marrow with healthy stem cells to treat malignancies like lymphoma, leukemia, and myeloma. Market momentum is largely driven by the increasing incidence of blood cancers and technological breakthroughs in haploidentical transplantation, which allow for donors beyond fully matched siblings. Global efforts to boost donor pools further support this growth; the World Marrow Donor Association noted in 2024 that the international registry included over 44 million volunteer donors and cord blood products, significantly improving match probabilities for diverse patients.

However, the market faces a substantial hurdle in the form of high costs related to the procedure and long-term management. The financial strain encompasses pre-transplant conditioning, the surgery itself, and extended care for complications such as graft-versus-host disease. This economic burden restricts access, especially in areas with developing healthcare infrastructure or insufficient reimbursement systems.

Market Driver

The rising incidence of hematologic malignancies stands as the primary engine for market growth, with conditions like leukemia, myeloma, and lymphoma often requiring hematopoietic stem cell transplantation (HSCT) as a curative measure. This growing cancer burden drives a continuous demand for transplant procedures globally. Highlighting this trend, the American Cancer Society's "Cancer Facts & Figures 2025" report from January 2025 projected 66,890 new leukemia diagnoses and 89,070 lymphoma cases in the United States for that year alone, emphasizing the critical reliance on these therapies for managing life-threatening blood disorders.

Furthermore, technological refinements in HSCT, specifically regarding haploidentical protocols, have widened the market by mitigating donor shortages. Innovations in graft-versus-host disease (GVHD) prophylaxis, such as post-transplant cyclophosphamide, have established partially matched family donors as a standard option, lessening the need for fully matched unrelated donors. The Center for International Blood and Marrow Transplant Research reported in August 2025 that haploidentical related donors comprised 21% of all allogeneic transplants in 2023. This broadened eligibility is reflected in procedure volumes; the European Society for Blood and Marrow Transplantation's February 2025 report noted 47,731 transplants in 2023, marking a 7.8% rise in allogeneic activity from the previous year.

Market Challenge

The substantial expenses linked to bone marrow transplantation and ongoing care serve as a major impediment to market growth. This financial barrier stems from the intricate nature of the procedure, rigorous pre-transplant conditioning, and necessary long-term post-operative monitoring. Consequently, patients without adequate insurance and healthcare systems operating on restricted budgets are often unable to access these life-saving therapies, reducing the potential market size. Additionally, the high capital investment required for specialized facilities limits availability primarily to affluent regions, leaving populations in developing healthcare infrastructures underserved.

The economic pressure is intensified by the cost of managing complications such as graft-versus-host disease, which requires expensive medication and potential hospital readmissions. According to the American Society of Hematology, the median healthcare cost per patient during the transplant period alone was approximately $331,827 in 2024. These prohibitive costs frequently result in high claim denial rates by payers or substantial out-of-pocket burdens for patients, creating economic friction that restricts the annual volume of procedures despite increasing clinical demand.

Market Trends

The rise of gene-edited hematopoietic stem cell therapies marks a paradigm shift in the industry, offering curative treatments for genetic blood disorders that do not rely on matched donors. This trend involves the commercialization of autologous stem cells modified ex vivo to rectify genetic errors, thereby eliminating graft-versus-host disease risks and expanding patient eligibility. The market viability of this approach is evident in recent financial data; in November 2025, Vertex Pharmaceuticals reported in its third-quarter results that its gene-edited therapy, Casgevy, achieved $17 million in revenue, highlighting the rapid adoption and immediate impact of these advanced genetic interventions.

Simultaneously, the integration of artificial intelligence into donor matching is revolutionizing the pre-transplant process by improving human leukocyte antigen (HLA) selection and risk assessment. Advanced machine learning algorithms are now utilized to interpret complex biological data, enabling clinicians to forecast transplant outcomes and complications with greater accuracy than traditional methods. This shift toward data-driven precision is enhancing care standards; GlobalRPH reported in March 2025 that custom AI models recently attained an 89% precision rate in predicting stem cell transplant survival, signaling a distinct evolution toward personalized medicine within the sector.

Key Market Players

• Merck KGaA
• SANOFI WINTHROP INDUSTRIE
• AllCells, LLC
• STEMCELL Technologies Canada Inc.
• American Type Culture Collection
• Charles River Laboratories International, Inc.
• Fujifilm Cellular Dynamics, Inc.
• ReachBio LLC
• PromoCell GmbH
• Mesoblast Ltd

Report Scope

In this report, the Global Bone Marrow Transplant Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bone Marrow Transplant Market, By Type

• Autologous Transplant
• Allogenic Transplant
• Others

Bone Marrow Transplant Market, By Treatment Type

• Leukemia
• Lymphoma
• Myeloma
• Myelodysplastic Syndrome
• Myeloproliferative Disorders
• Aplastic Anemia
• Solid Tumors
• Sickle cell Anemia
• Thalassemia
• Others

Bone Marrow Transplant Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bone Marrow Transplant Market.

Available Customizations:

Global Bone Marrow Transplant Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bone Marrow Transplant Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Autologous Transplant, Allogenic Transplant, Others)
  • 5.2.2. By Treatment Type (Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndrome, Myeloproliferative Disorders, Aplastic Anemia, Solid Tumors, Sickle cell Anemia, Thalassemia, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Bone Marrow Transplant Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bone Marrow Transplant Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment Type
  • 6.3.2. Canada Bone Marrow Transplant Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment Type
  • 6.3.3. Mexico Bone Marrow Transplant Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment Type

7. Europe Bone Marrow Transplant Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bone Marrow Transplant Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment Type
  • 7.3.2. France Bone Marrow Transplant Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment Type
  • 7.3.3. United Kingdom Bone Marrow Transplant Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment Type
  • 7.3.4. Italy Bone Marrow Transplant Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment Type
  • 7.3.5. Spain Bone Marrow Transplant Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment Type

8. Asia Pacific Bone Marrow Transplant Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Bone Marrow Transplant Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment Type
  • 8.3.2. India Bone Marrow Transplant Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment Type
  • 8.3.3. Japan Bone Marrow Transplant Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment Type
  • 8.3.4. South Korea Bone Marrow Transplant Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment Type
  • 8.3.5. Australia Bone Marrow Transplant Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment Type

9. Middle East & Africa Bone Marrow Transplant Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Bone Marrow Transplant Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment Type
  • 9.3.2. UAE Bone Marrow Transplant Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment Type
  • 9.3.3. South Africa Bone Marrow Transplant Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment Type

10. South America Bone Marrow Transplant Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Bone Marrow Transplant Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment Type
  • 10.3.2. Colombia Bone Marrow Transplant Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment Type
  • 10.3.3. Argentina Bone Marrow Transplant Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Bone Marrow Transplant Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck KGaA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. SANOFI WINTHROP INDUSTRIE
• 15.3. AllCells, LLC
• 15.4. STEMCELL Technologies Canada Inc.
• 15.5. American Type Culture Collection
• 15.6. Charles River Laboratories International, Inc.
• 15.7. Fujifilm Cellular Dynamics, Inc.
• 15.8. ReachBio LLC
• 15.9. PromoCell GmbH
• 15.10. Mesoblast Ltd

16. Strategic Recommendations

17. About Us & Disclaimer